The global bispecific antibody market is expected to reach $500 million by the end of 2023, and $1 billion by 2033, representing a 7.2% CAGR.
The bispecific antibody business has benefited greatly from antibody engineering. Much progress has been achieved in generating innovative antibody formats and engineering procedures that allow the creation of bispecific antibodies with improved efficacy and stability in recent years. Advances in recombinant DNA technology and protein engineering, for example, have permitted the development of bispecific antibodies with enhanced pharmacokinetics, lower immunogenicity, and higher tumour penetration.
The rising prevalence of cancer and autoimmune illnesses is also driving the bispecific antibody market. These disorders continue to be a large unmet medical need, and developing novel and effective therapeutics is critical for improving patient outcomes. Bispecific antibodies show promise in the treatment of cancer and autoimmune illnesses because they can target two distinct antigens at the same time, increasing therapeutic efficacy. For example, blinatumomab, a bispecific antibody targeting CD19 and CD3, has been licenced for the treatment of B-cell acute lymphoblastic leukaemia (ALL) and is being tested for other hematologic cancers.
Bispecific Antibody Market: Segmentation
By Drug Type:
- Blinatumomab
- Catumaxomab
- Duligotumab
By Indication:
- Cancer
- Infectious Disease
- Inflammatory and Autoimmune Disorders
- CNS Disorders
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drugstores
- Online Pharmacies
Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and list of tables.
Read More@ https://www.futuremarketinsights.com/reports/bispecific-antibody-market
Competitive Analysis
By Prominent Market Players
- Sonafi S.A.
- AbbVie Inc.
- Pfizer Inc.
- Johnson & Johnson
- Portola Pharmaceuticals
- Bristol-Myers Squibb
- Ganymed Pharmaceuticals
- OncoMed Pharmaceuticals
- Merck Amgen
- Bayer AG
- Daiichi Sankyo Company Limited
Global Bispecific Antibody Market is valued at USD 489.7 Million in 2020 and expected to reach USD 810.4 Million by 2027 with the CAGR of 6.5% over the forecast period.Scope of Global Bispecific Antibody Market ReportBispecific antibody is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen.
Most of the bispecific antibodies are being developed for the treatment of multiple cancers followed by infectious disease, CNS disorders, inflammatory and autoimmune disorders.You Can Download 200 Pages PDF Copy of Bispecific Antibody Market @ https://brandessenceresearch.com/requestSample/PostId/1129?utm_source=Free_medium=ARThe benefits of bispecific antibodies over monoclonal therapeutics are due to their higher binding avidity to targets, which can interact with more than one surface antigen and boosted cytotoxic effects.
It is because of the direct recruitment of effector cells to the site of the disease or in tumorigenic conditions.
Bispecific antibodies may be used to improve clinical efficacy by targeting two disease mechanisms for the treatment of complex human diseases in a single agent.Bispecific antibodies also hold promise for certain therapeutic applications difficult to achieve by single-targeting monospecific antibodies, such as immune cell retargeting, site-specific targeting, enabling therapeutics to cross the blood–brain barrier, and unique receptor modulation.Bispecific antibodies (bsAbs) combine the specificities of two antibodies to target separate antigens or epitopes at the same time.
BsAbs with 'two target' functionality can bind to several receptors or ligands on the surface of cells.
Top Companies:Key Players for Global Bispecific Antibody Market Report– Oncomed Pharmaceuticals, Abbvie, Bayer AG, Janseen Biotech, Fabion Pharmaceuticals, Novartis AG, Pfizer Inc., ImmunGene, Inc., Celgene, Amgen Inc., Immunocore Limited, Merck & Co., Inc., Paktis Antibody Services GmBH, Ganymed Pharmaceuticals, Dow Pharmaceutical Solutions, and F. Hoffmann-La Roche AG others.Get Full Report @ https://brandessenceresearch.com/healthcare/bispecific-antibody-market-sizeSegmentation Analysis:Global Bispecific Antibody Market is segmented on the basis of product types, applications, and region & country level.
Market Analysis: Global Bispecific Antibody MarketGlobal bispecific antibody market is expected to grow at a growing CAGR in the forecast period of 2019-2026.
Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth.Global Bispecific Antibody Market By Type (Immunoglobulin G (IgG) Like Molecule, Non Immunoglobulin G (IgG) Like Molecule), Mechanism of Action (Bispecific Diabodies, Bispecific T-Cell Engager Antibodies), Application (Oncology, Autoimmune Disease and Others), Drugs (Blinatumomab, Catumaxomab, Duligotumab and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026Get Exclusive Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bispecific-antibody-marketMarket Definition: Global Bispecific Antibody MarketBispecific antibodies are designed to elicit multifaceted biological effects that require simultaneous binding to two different antigen targets with one molecule.
It can be employed wide range of therapeutics application including bind multiple targets, to block multiple pathogenic pathways, target tumor heterogeneity, increase specificity, synergistically induce enhanced therapeutic effects and others.Market DriversOngoing clinical trial conducted by many pharmaceuticals industries is propelling the growth of this marketIncrease in special designation from the regulatory authorities is boosting the market growthMajor advancements in linker technology is likely to drive the marketHigh demand of disease specific novel treatment can also act as a market driverThe competitive scenario of market and strategic collaborations may boost the market positionMarket RestraintsLimited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this marketLow healthcare budget in some developing countries is hamper the market growthPatent expiration of branded drugs and introduction of generics is also hinders the market growthKnow more about this report https://www.databridgemarketresearch.com/reports/global-bispecific-antibody-marketCompetitive Analysis:Global bispecific antibody market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
The report includes market shares global bispecific antibody market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.Key Market Players:Few of the major competitors currently working in the global bispecific antibody market are Adimab, Innovent Biologics, Inc, Affimed GmbH, Amgen Inc, AstraZeneca, Xencor, Sanofi, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Eli Lilly and Company, Xencor, Pieris Pharmaceuticals, Inc, Mereo BioPharma Group plc, Sobi, TG Therapeutics, Inc, Merus, MacroGenics, Inc, Genmab A/S, Emergent BioSolutions Inc, Alteogen, Astellas Pharma Inc, Novartis AG, CELGENE CORPORATION and others.Get Access Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-bispecific-antibody-marketResearch Methodology: Global Bispecific Antibody MarketData collection and base year analysis is done using data collection modules with large sample sizes.
The market data is analysed and forecasted using market statistical and coherent models.
Also market share analysis and key trend analysis are the major success factors in the market report.
